Regulation of drug metabolism and disposition during inflammation and infection

Bibliography

• RENTON KW: Relationships between the enzymes of detoxication and host defence mechanisms. In: Biological basis of detoxication. J Caldwell, WB Jacoby (Eds), Academic Press, New York, US (1983):307–324.
   Google Scholar
• RENTON KW: Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr. Drug Metab. (2004) 5:235–243.
   PubMed Web of Science ®Google Scholar
• MORGAN ET, LI-MASTERS T, CHENG PY: Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology (2002) 181–182:207–210.
   PubMed Web of Science ®Google Scholar
• MORGAN ET: Regulation of cytochromes P450 during inflammation and infection. Drug Metab. Rev. (1997) 29:1129–1188.
   PubMed Web of Science ®Google Scholar
• RENTON KW: Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol. Ther. (2001) 92:147–163.
   PubMed Web of Science ®Google Scholar
• MORGAN ET: Regulation of cytochrome P450 by inflammatory mediators: why and how? Drug Metab. Dispos. (2001) 29:207–212.
   PubMed Web of Science ®Google Scholar
• SAMARAS SC, DEITZ N: Physiopathology of detoxification of pentobarbital sodium. Fed. Am. Soc. Exp. Biol. (1953) 12:400.
   Google Scholar
• RENTON KW, MANNERING GJ: Depression of the hepatic cytochrome P450 mono-oxygenase system by administered tilorone (2,7-bis(2- (diethylamino)ethoxy)fluoren-9-one dihydrochloride). Drug Metab. Dispos. (1976) 4:223–231.
   PubMed Web of Science ®Google Scholar
• RENTON KW, MANNERING GJ: Depression of hepatic cytochrome P450- dependent monooxygenase systems with administered interferon inducing agents. Biochem. Biophys. Res. Commun. (1976) 73:343–348.
   PubMed Web of Science ®Google Scholar
• MORGAN ET: Regulation of cytochrome P450 by inflammatory mediators: why and how? Drug Metab. Dispos. (2001) 29:207–212.
   PubMed Web of Science ®Google Scholar
• FUKUDA Y, ISHIDA N, NOGUCHI T, KAPPAS A, SASSA S: Interleukin-6 down regulates the expression of transcripts encoding cytochrome P450 1A1, 1A2 and III3A in human hepatoma cells. Biochem. Biophys. Res. Comm. (1992) 184:960–965.
   PubMed Web of Science ®Google Scholar
• FUKADA Y, SASSA S: Supression of cytochrome P4501A1 by interleukin-6 in human hepaG2 hepatoma cells. Biochem. Pharmacol. (1994) 47:1187–1195.
   PubMed Web of Science ®Google Scholar
• CLARK MA, BING BA, GOTTSCHALL PE, WILLIAMS JF: Differential effect of cytokines on the phenobarbital or 3- methylcholanthrene induction of P450 mediated monooxygenase activity in cultured rat hepatocytes. Biochem. Pharmacol. (1995) 49:97–104.
   PubMed Web of Science ®Google Scholar
• SANNE JL, KRUEGER KE: Expression of cytochrome P450 side-chain cleavage enzyme and 3 β-hydroxysteroid dehydrogenase in the rat central nervous system: a study by polymerase chain reaction and in situ hybridization. J. Neurochem. (1995) 65:528–536.
   PubMed Web of Science ®Google Scholar
• WRIGHT K, MORGAN ET: Regulation of cytochrome P450IIC12 expression by interleukin-1α, interleukin-6 and dexamethasone. Mol. Pharmacol. (1991) 39:468–474.
   PubMed Web of Science ®Google Scholar
• NADIN L, BUTLER AM, FARRELL GC, MURRAY M: Pretranslational downregulation of cytochromes P450 2C11 and 3A2 in male rat liver by tumor necrosis factor α. Gastroenterology (1995) 109:198–205.
   PubMed Web of Science ®Google Scholar
• TINEL M, ROBIN MA, DOOSTZADEH J et al. : The interleukin-2 receptor down-regulates the expression of cytochrome P450 in cultured rat hepatocytes. Gastroenterology (1995) 109:1589–1599.
   PubMed Web of Science ®Google Scholar
• HERRMANN M, SCHOLMERICH J, STRAUB RH: Influence of cytokines and growth factors on distinct steroidogenic enzymes in vitro: a short tabular data collection. Ann. NY Acad. Sci. (2002) 966:166–186.
   PubMed Web of Science ®Google Scholar
• PARKINSON A, LASKER J, KRAMER MJ et al. : Effects of three recombinant human leukocyte interferons on drug metabolism in mice. Drug Metab. Dispos. (1982) 10:579–585.
   PubMed Web of Science ®Google Scholar
• SINGH G, RENTON KW, STEBBING N: Homogeneous interferon from E. coli depresses hepatic cytochrome P450 and drug biotransformation. Biochem. Biophys. Res. Commun. (1982) 106:1256–1261.
   PubMed Web of Science ®Google Scholar
• CALLEJA C, EECKHOUTTE C, DACASTO M et al. : Comparative effects of cytokines on constitutive and inducible expression of the gene encoding for the cytochrome P450 3A6 isoenzyme in cultured rabbit hepatocytes: consequences on progesterone 6β-hydroxylation. Biochem. Pharmacol. (1998) 56:1279–1285.
   PubMed Web of Science ®Google Scholar
• CARELLI M, PORRAS MC, RIZZARDINI M, CANTONI L: Modulation of constitutive and inducible hepatic cytochrome(s) P450 by interferon-β in mice. J. Hepatol. (1996) 24:230–237.
   PubMed Web of Science ®Google Scholar
• ISLAM M, FRYE RF, RICHARDS TJ et al. : Differential effect of IFN-α2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin. Cancer Res. (2002) 8:2480–2487.
   PubMed Web of Science ®Google Scholar
• KUROKOHCHI K, YONEYAMA H, MATSUO Y, NISHIOKA M, ICHIKAWA Y: Effects of interleukin 1α on the activities and gene expressions of the cytochrome P450IID subfamily. Biochem. Pharmacol. (1992) 44:1669–1674.
   PubMed Web of Science ®Google Scholar
• MORGAN ET, THOMAS KB, SWANSON R, VALES T, HWANG J, WRIGHT K: Selective suppression of cytochrome P450 gene expression by interleukins 1 and 6 in rat liver. Biochim. Biophys. Acta (1994) 1219:475–483.
   PubMed Web of Science ®Google Scholar
• CHEN YL, FLORENTIN I, BATT AM, FERRARI L, GIROUD JP, CHAUVELOT-MOACHON L: Effects of interleukin-6 on cytochrome P450- dependent mixed-function oxidases in the rat. Biochem. Pharmacol. (1992) 44:137–148.
   PubMed Web of Science ®Google Scholar
• CHEN YL, LE VRAUX V, LENEVEU A et al. : Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin. Pharmacol. Ther. (1994) 55:649–660.
   PubMed Web of Science ®Google Scholar
• WARREN GW, VAN ESS PJ, WATSON AM, MATTSON MP, BLOUIN RA: Cytochrome P450 and antioxidant activity in interleukin-6 knockout mice after induction of the acutephase response. J. Interferon Cytokine Res. (2001) 21:821–826.
   PubMed Web of Science ®Google Scholar
• SIEWERT E, BORT R, KLUGE R, HEINRICH PC, CASTELL J, JOVER R: Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology (2000) 32:49–55.
   PubMed Web of Science ®Google Scholar
• WRIGHT K, MORGAN ET: Transcriptional and post-transcriptional supression of P450IIC11 and P450IIC12 by inflammation. FEBS Lett. (1990) 271:59–61.
   PubMed Web of Science ®Google Scholar
• DELAPORTE E, CRIBB AE, RENTON KW: Interferon-mediated changes in the expression of CYP1A1 in human B lymphoblastoid (AHH-1 TK+/-) cells. Can. J. Physiol. Pharmacol. (1995) 73:1692–1697.
   PubMed Web of Science ®Google Scholar
• DELAPORTE E, RENTON KW: Cytochrome P4501A1 and cytochrome P4501A2 are downregulated at both transcriptional and post-transcriptional levels by conditions resulting in interferon-α/β induction. Life Sci. (1997) 60:787–796.
   PubMed Web of Science ®Google Scholar
• CHEN JQ, STROM A, GUSTAFSSON JA, MORGAN ET: Suppression of the constitutive expression of cytochrome P450 2C11 by cytokines and interferons in primary cultures of rat hepatocytes: comparison with induction of acute-phase genes and demonstration that CYP2C11 promoter sequences are involved in the suppressive response to interleukins 1 and 6. Mol. Pharmacol. (1995) 47:940–947.
   PubMed Web of Science ®Google Scholar
• MOOCHHALA S, RENTON KW: The effect of IFN-α-Con1 on hepatic cytochrome P450 and protein. Int. J. Immunopharmacol. (1991) 13:903–912.
   PubMed Web of Science ®Google Scholar
• MOREL Y, BAROUKI R: Downregulation of cytochrome P450 1A1 gene promoter by oxidative stress - critical contribution of nuclear factor 1. J. Biol. Chem. (1998) 273:26969–26976.
   PubMed Web of Science ®Google Scholar
• IBER H, CHEN Q, CHENG PY, MORGAN ET: Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-êB binding at the transcription start site. Arch. Biochem. Biophys. (2000) 377:187–194.
   PubMed Web of Science ®Google Scholar
• GORALSKI KB, ABDULLA D, SINAL CJ, ARSENAULT A, RENTON KW: Toll-like receptor-4 regulation of hepatic Cyp3a11 metabolism in a mouse model of LPS-induced CNS inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. (2005) 289:G434–G443.
   PubMed Web of Science ®Google Scholar
• VAN ESS PJ, MATTSON MP, BLOUIN RA: Enhanced induction of cytochrome P450 enzymes and CAR binding in TNF (p55-/-/p75-/-) double receptor knockout mice following phenobarbital treatment. J. Pharmacol. Exp. Ther. (2002) 300:824–830.
   PubMed Web of Science ®Google Scholar
• SACHDEVA K, YAN B, CHICHESTER CO: Lipopolysaccharide and cecal ligation/puncture differentially affect the subcellular distribution of the pregnane X receptor, but consistently cause suppression of its target genes CYP3A. Shock (2003) 19:469–474.
   PubMed Web of Science ®Google Scholar
• BEIGNEUX AP, MOSER AH, SHIGENAGA JK, GRUNFELD C, FEINGOLD KR: Reduction in cytochrome P450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem. Biophys. Res. Commun. (2002) 293:145–149.
   PubMed Web of Science ®Google Scholar
• MORGAN ET: Suppression of constitutive cytochrome P450 gene expression in livers of rats undergoing an acute phase response to endotoxin. Mol. Pharmacol. (1989) 36:699–707.
   PubMed Web of Science ®Google Scholar
• HAKKOLA J, HU Y, INGELMAN-SUNDBERG M: Mechanisms of down-regulation of CYP2E1 expression by inflammatory cytokines in rat hepatoma cells. J. Pharmacol. Exp. Ther. (2003) 304:1048–1054.
   PubMed Web of Science ®Google Scholar
• CHANG KC, LAUER BA, BELL TD, CHAI H: Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet (1978) 1:1132–1133.
   PubMed Web of Science ®Google Scholar
• RENTON KW: Altered theophylline kinetics. Lancet (1978) 2:160–161.
   Google Scholar
• FLEETHAM JA, NAKATSU K, MUNT PW: Theophylline pharmacokinteics and respiratory infections. Lancet (1978) 2:898.
   Web of Science ®Google Scholar
• CLARKE CJ, BOYD G: Theophylline pharmacokinetics during respiratory viral infection. Lancet (1979) 1:492.
   Web of Science ®Google Scholar
• WALKER SB, MIDDLEKAMP JN: Theophylline toxicity and viral infection. Pediatrics (1982) 70:508.
   Google Scholar
• GREENWALD M, KOREN G: Viral induced changes in theophylline handling in children. Am J. Asthma Allergy Pediatr. (1990) 3:162.
   Google Scholar
• WOO OF, KOUP JR, KRAEMER M, ROBERTSON WO: Acute intoxication with theophylline while on chronic therapy. Vet and Human Toxicol. (1980) 22:48–51.
   Google Scholar
• KRAEMER MJ, FURUKAWA C, KOUP JP, SHAPIRO G: Altered theophylline clearance during an influenza outbreak. Pediatrics (1982) 69:476–480.
   PubMed Web of Science ®Google Scholar
• KOREN G, GREENWALD M: Decrease in theophylline clearance causing toxicity during viral epidemics. J. Asthma (1985) 22:75–79.
   PubMed Web of Science ®Google Scholar
• BLEAU AM, FRADETTE C, EL-KADI AOS, COTE MC, DU SOUICH P: Cytochrome P450 downregulation by serum from humans with a viral infection and from rabbits with an inflammatory reaction. Drug Metab. Dispos. (2001) 29:1007–1012.
   PubMed Web of Science ®Google Scholar
• BLEAU AM, LEVITCHI MC, MAURICE H, DU SOUICH P: Cytochrome P450 inactivation by serum from humans with a viral infection and serum from rabbits with a turpentineinduced inflammation: the role of cytokines. Br. J. Pharmacol. (2000) 130:1777–1784.
   PubMed Web of Science ®Google Scholar
• BLEAU AM, MAUREL P, PICHETTE V, LEBLOND F, DU SOUICH P: Interleukin-1β, interleukin-6, tumour necrosis factor-α and interferon-γ released by a viral infection and an aseptic inflammation reduce CYP1A1, 1A2 and 3A6 expression in rabbit hepatocytes. Eur. J. Pharmacol. (2003) 473:197–206.
   PubMed Web of Science ®Google Scholar
• ANOLIK R, KOLSKI GB, SCHAIBLE DH, RATNER J: Transient alteration of theophylline half-life: possible association with Herpes simplex infection. Ann. Allergy (1982) 49:109–111.
   PubMedGoogle Scholar
• FORSYTH JS, MORELAND TA, RYELANCE GW: The effect of fever on antipyrine metabolism in children. Br. J. Clin. Pharmacol. (1982) 13:811–815.
   PubMed Web of Science ®Google Scholar
• LEE BL, WONG D, BENOWITZ NL, SULLAM PM: Altered patterns of drug metabolism in patients with aquired immunodeficiency syndrome. Clin. Pharmacol. Ther. (1993) 53:529–535.
   PubMed Web of Science ®Google Scholar
• KIRBY GM, BATIST G, ALPERT L, LAMOUREUX E, CAMERON RG, ALAOUI-JAMALI MA: Overexpression of cytochrome P450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis. Toxicol. Pathol. (1996) 24:458–467.
   PubMed Web of Science ®Google Scholar
• PASANEN M, RANNALA Z, TOOMING A, SOTANIEMI EA, PELKONEN O, RAUTIO A: Hepatitis A impairs the function of human hepatic CYP2A6 in vivo. Toxicology (1997) 123:177–184.
   PubMed Web of Science ®Google Scholar
• BECQUEMONT L, CHAZOUILLERES O, SERFATY L et al. : Effect of interferon α-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Clin. Pharmacol. Ther. (2002) 71:488–495.
   PubMed Web of Science ®Google Scholar
• O’NEIL WM, GILFIX BM, MARKOGLOU N, DI GIROLAMO A, TSOUKAS CM, WAINER IW: Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome. Eur. J. Clin. Pharmacol. (2000) 56:231–240.
   PubMed Web of Science ®Google Scholar
• TONG JZ, DE LAGAUSIE P, FURLAN V, CRESTEIL T, BERNARD O, ALVAREZ F: Long-term culture of adult rat hepatocyte spheroids. Exp. Cell Res. (1992) 200:326–332.
   PubMed Web of Science ®Google Scholar
• TRELUYER JM, BENECH H, COLIN I, PRUVOST A, CHERON G, CRESTEILT: Ontogenesis of CYP2Cdependent arachidonic acid metabolism in the human liver: relationship with sudden infant death syndrome. Pediatr. Res. (2000) 47:677–683.
   PubMed Web of Science ®Google Scholar
• TRELUYER JM, CHERON G, SONNIER M, CRESTEIL T: Cytochrome P450 expression in sudden infant death syndrome. Biochem. Pharmacol. (1996) 52:497–504.
   PubMed Web of Science ®Google Scholar
• BEURTON F, GUERET G, HORISBERGER M, CHERON G, CRESTEIL T: Transcriptional activation of CYP2C, MxA and Fas in sudden infant death syndrome. Int J. Mol. Med. (1999) 3:33–39.
   PubMed Web of Science ®Google Scholar
• DE PAEPE P, BELPAIRE FM, BUYLAERT WA: Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin. Pharmacokinet. (2002) 41:1135–1151.
   PubMed Web of Science ®Google Scholar
• CARCILLO JA, DOUGHTY L, KOFOS D et al. : Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med. (2003) 29:980–984.
   PubMed Web of Science ®Google Scholar
• SHEDLOFSKY SI, ISRAEL BC, MCCLAIN CJ, HILL DB, BLOUIN RA: Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J. Clin. Invest. (1994) 94:2209–2214.
   PubMed Web of Science ®Google Scholar
• SHEDLOFSKY SI, ISRAEL BC, TOSHEVA R, BLOUIN RA: Endotoxin depresses hepatic cytochrome P450- mediated drug metabolism in women. Br. J. Clin. Pharmacol. (1997) 43:627–632.
   PubMed Web of Science ®Google Scholar
• TOFT P, HESLET L, HANSEN M, KLITGAARD NA: Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure. Intensive Care Med. (1991) 17:465–468.
   PubMed Web of Science ®Google Scholar
• SHELLY MP, MENDEL L, PARK GR: Failure of critically ill patients to metabolise midazolam. Anaesthesia (1987) 42:619–626.
   PubMed Web of Science ®Google Scholar
• PARK GR, MILLER E, NAVAPURKAR V: What changes drug metabolism in critically ill patients? - II Serum inhibits the metabolism of midazolam in human microsomes. Anaesthesia (1996) 51:11–15.
   PubMed Web of Science ®Google Scholar
• GIANNINI E, FASOLI A, BORRO P et al. : Impairment of cytochrome P450- dependent liver activity in cirrhotic patients with Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2001) 15:1967–1973.
   PubMed Web of Science ®Google Scholar
• PRESCOTT LF: Therapeutic misadventure with paracetamol: fact or fiction? Am. J. Ther. (2000) 7:99–114.
   Google Scholar
• PRANDOTA J: Unusual distribution, pharmacokinetics, and metabolism of some drugs and their implications to pharmacotherapy. Am. J. Ther. (2000) 7:332–340.
   PubMedGoogle Scholar
• HAAS CE, KAUFMAN DC, JONES CE, BURSTEIN AH, REISS W: Cytochrome P450 3A4 activity after surgical stress. Crit. Care Med. (2003) 31:1338–1346.
   PubMed Web of Science ®Google Scholar
• FRYE RF, SCHNEIDER VM, FRYE CS, FELDMAN AM: Plasma levels of TNF-α and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J. Card. Fail. (2002) 8:315–319.
   PubMed Web of Science ®Google Scholar
• FRADETTE C, BLEAU AM, PICHETTE V, CHAURET N, DU SOUICH P: Hypoxia-induced downregulation of CYP1A1/1A2 and upregulation of CYP3A6 involves serum mediators. Br. J. Pharmacol. (2002) 137:881–891.
   PubMed Web of Science ®Google Scholar
• BAER AN, MCALLISTER CB, WILKINSON GR, WOOSLEY RL, PINCUS T: Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis Rheum. (1986) 29:843–850.
   PubMed Web of Science ®Google Scholar
• MAYO PR, SKEITH K, RUSSELL AS, JAMALI F: Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br. J. Clin. Pharmacol. (2000) 50:605–613.
   PubMed Web of Science ®Google Scholar
• DULOS J, VAN DER VLEUTEN MA, KAVELAARS A, HEIJNEN CJ, BOOTS AM: CYP7B expression and activity in fibroblast-like synoviocytes from patients with rheumatoid arthritis: regulation by proinflammatory cytokines. Arthritis Rheum. (2005) 52:770–778.
   PubMed Web of Science ®Google Scholar
• SLAVIERO KA, CLARKE SJ, RIVORY LP: Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol. (2003) 4:224–232.
   PubMed Web of Science ®Google Scholar
• RIVORY LP, SLAVIERO K, SEALE JP et al. : Optimizing the erythromycin breath test for use in cancer patients. Clin. Cancer Res. (2000) 6:3480–3485.
   PubMed Web of Science ®Google Scholar
• RIVORY LP, SLAVIERO KA, CLARKE SJ: Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br. J. Cancer (2002) 87:277–280.
   PubMed Web of Science ®Google Scholar
• IBACH B, APPEL K, GEBICKEHAERTER P et al.: Effect of phenytoin on cytochrome P450 2B mRNA expression in primary rat astrocyte cultures. J. Neurosci. Res. (1998) 54:402–411.
   PubMed Web of Science ®Google Scholar
• HONMA S, SHIMODAIRA K, SHIMIZU Y et al. : The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells. Endocr. J. (2002) 49:371–377.
   PubMed Web of Science ®Google Scholar
• ROTHWELL NJ, LUHESHI G, TOULLAND S: Cytokines and their receptors in the central nervous system: physiology, pharmacology and pathology. Pharmacol. Ther. (1996) 69:85–95.
   PubMed Web of Science ®Google Scholar
• RENTON KW, DIBB S, LEVATTE TL: Lipopolysaccharide evokes the modulation of brain cytochrome P4501A in the rat. Brain Res. (1999) 842:139–147.
   PubMed Web of Science ®Google Scholar
• MONSHOUWER M, AGNELLO D, GHEZZI P, VILLA P: Decrease in brain cytochrome P450 enzyme activities during infection and inflammation of the central nervous system. Neuroimmunomodulation (2000) 8:142–147.
   PubMed Web of Science ®Google Scholar
• NICHOLSON TE, RENTON KW: Role of cytokines in the lipopolysaccharideevoked depression of cytochrome P450 in the brain and liver. Biochem. Pharmacol. (2001) 62:1709–1717.
   PubMed Web of Science ®Google Scholar
• NICHOLSON TE, RENTON KW: The role of cytokines in the depression of CYP1A activity using cultured astrocytes as an in vitro model of inflammation in the central nervous system. Drug Metab. Dispos. (2002) 30:42–46.
   PubMed Web of Science ®Google Scholar
• GORALSKI KB, RENTON KW: Brain inflammation enhances 1-methyl-4- phenylpyridinium-evoked neurotoxicity in rats. Toxicol. Appl. Pharmacol. (2004) 196:381–389.
   PubMed Web of Science ®Google Scholar
• SHIMAMOTO Y, KITAMURA H, HOSHI H et al. : Differential alterations in levels of hepatic microsomal cytochrome P450 isozymes following intracerebroventricular injection of bacterial lipopolysaccharide in rats. Arch. Toxicol. (1998) 72:492–498.
   PubMed Web of Science ®Google Scholar
• SHIMAMOTO Y, KITAMURA H, IWAI M, SAITO M, KAZUSAKA A, FUJITA S: Mechanism of decrease in levels of hepatic P450 isozymes induced by intracerebral endotoxin: independence from sympathetic nervous and adrenocortical systems. Arch. Toxicol. (1999) 73:41–49.
   PubMed Web of Science ®Google Scholar
• ABDULLA D, GORALSKI KB, DEL BUSTO CANO EG, RENTON KW: The signal transduction pathways involved in hepatic cytochrome P450 regulation in the rat during a lipopolysaccharide-induced model of central nervous system inflammation. Drug Metab. Dispos. (2005) 33:1521–1531.
   PubMed Web of Science ®Google Scholar
• DEL BUSTO CANO EG, RENTON KW: Modulation of hepatic cytochrome P450 during Listeria monocytogenes infection in the brain. J. Pharm. Sci. (2003) 92:1860–1868.
   PubMed Web of Science ®Google Scholar
• GORALSKI KB, HARTMANN G, PIQUETTE-MILLER M, RENTON KW: Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br. J. Pharmacol. (2003) 139:35–48.
   PubMed Web of Science ®Google Scholar
• NICHOLSON TE, RENTON KW: Modulation of cytochrome P450 by inflammation in astrocytes. Brain Res. (1999) 827:12–18.
   PubMed Web of Science ®Google Scholar
• PIQUETTE-MILLER M, PAK A, KIM H, ANARI R, SHAHZAMMI A: Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharmaceutical Res. (1998) 15:706–711.
   PubMed Web of Science ®Google Scholar
• HARTMANN G, KIM H, PIQUETTE-MILLER M: Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int. Immunopharmacol. (2001) 1:189–199.
   PubMed Web of Science ®Google Scholar
• HARTMANN G, CHEUNG AK, PIQUETTE-MILLER M: Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J. Pharmacol. Exp. Ther. (2002) 303:273–281.
   PubMed Web of Science ®Google Scholar
• SUKHAI M, YONG A, PAK A, PIQUETTE-MILLER M: Decreased expression of P-glycoprotein in interleukin-1β and interleukin-6 treated rat hepatocytes. Inflamm. Res. (2001) 50:362–370.
   PubMed Web of Science ®Google Scholar
• MCRAE MP, BROUWER KL, KASHUBA AD: Cytokine regulation of P-glycoprotein. Drug Metab. Rev. (2003) 35:19–33.
   PubMed Web of Science ®Google Scholar
• RENTON KW, NICHOLSON TE: Hepatic and central nervous system cytochrome P450 are down-regulated during lipopolysaccharide-evoked localized inflammation in brain. J. Pharmacol. Exp. Ther. (2000) 294:524–530.
   PubMed Web of Science ®Google Scholar
• KAWAGUCHI H, MATSUI Y, WATANABE Y, TAKAKURA Y: Effect of interferon-ã on the pharmacokinetics of digoxin, a P-glycoprotein substrate, intravenously injected into the mouse. J. Pharmacol. Exp. Ther. (2004) 308:91–96.
   PubMed Web of Science ®Google Scholar
• CASTAGNE V, BONHOMME-FAIVRE L, URIEN S et al. : Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice. Drug Metab. Dispos. (2004) 32:168–171.
   PubMed Web of Science ®Google Scholar
• BONHOMME-FAIVRE L, PELLOQUIN A, TARDIVEL S et al. : Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice. Anti-Cancer Drugs (2002) 13:51–57.
   PubMed Web of Science ®Google Scholar
• SERKOVA NJ, CHRISTIANS U, BENET LZ: Biochemical mechanisms of cyclosporine neurotoxicity. Mol. Interv. (2004) 4:97–107.
   PubMed Web of Science ®Google Scholar